- Home
- LPTH vs SLS Comparison
LPTH vs SLS Comparison
Compare LPTH & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- SLS
- Stock Information
- Founded
- LPTH 1985
- SLS 2012
- Country
- LPTH United States
- SLS United States
- Employees
- LPTH N/A
- SLS N/A
- Industry
- LPTH Semiconductors
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- SLS Health Care
- Exchange
- LPTH Nasdaq
- SLS Nasdaq
- Market Cap
- LPTH 229.5M
- SLS 233.7M
- IPO Year
- LPTH 1996
- SLS N/A
- Fundamental
- Price
- LPTH $8.87
- SLS $1.90
- Analyst Decision
- LPTH Strong Buy
- SLS Strong Buy
- Analyst Count
- LPTH 3
- SLS 1
- Target Price
- LPTH $6.83
- SLS $7.00
- AVG Volume (30 Days)
- LPTH 1.9M
- SLS 2.4M
- Earning Date
- LPTH 11-06-2025
- SLS 11-12-2025
- Dividend Yield
- LPTH N/A
- SLS N/A
- EPS Growth
- LPTH N/A
- SLS N/A
- EPS
- LPTH N/A
- SLS N/A
- Revenue
- LPTH $37,202,630.00
- SLS N/A
- Revenue This Year
- LPTH $50.36
- SLS N/A
- Revenue Next Year
- LPTH $7.77
- SLS N/A
- P/E Ratio
- LPTH N/A
- SLS N/A
- Revenue Growth
- LPTH 17.26
- SLS N/A
- 52 Week Low
- LPTH $1.40
- SLS $0.77
- 52 Week High
- LPTH $9.34
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- LPTH 69.28
- SLS 61.30
- Support Level
- LPTH $6.47
- SLS $1.55
- Resistance Level
- LPTH $8.40
- SLS $1.75
- Average True Range (ATR)
- LPTH 0.70
- SLS 0.10
- MACD
- LPTH 0.06
- SLS 0.03
- Stochastic Oscillator
- LPTH 85.46
- SLS 95.92
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.